Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
6,160 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07801287 | Iparomlimab/Tuvonralimab Plus SBRT and Lenvatinib for Perioperative Treatment of Potentially Resectable Intermediate-Stage HCC | recruiting | Phase 2 | 20 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT07802002 | A Prospective, Single-Arm Clinical Study of a Dietary Supplement for the Prevention of Acute Radiation-Induced Rectal Injury During Neoadjuvant Chemoradiotherapy for Rectal Cancer | recruiting | N/A | 23 | Sixth Affiliated Hospital, Sun Yat-sen UniversityOTHER |
| 1 |
| Sep 3, 2026 |
| clinicaltrials |
| NCT04913285 | A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors | recruiting | Phase 1 | 400 | Pierre Fabre MedicamentINDUSTRY | 7 | Sep 2, 2026 | clinicaltrials |
| NCT05319730 | A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B) | recruiting | Phase 1 / Phase 2 | 230 | Merck Sharp & Dohme LLCINDUSTRY | 14 | Sep 2, 2026 | clinicaltrials |
| NCT05559645 | Assessing an Oral EGFR Inhibitor, DZD9008 in Patients With Advanced Non-small Cell Lung Cancer(NSCLC) With EGFR Mutations (WU-KONG15)(WU-KONG15) | recruiting | N/A | 180 | Peking Union Medical College HospitalOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT05772273 | PD-1 Inhibitor, Azacitidine and Low-dose DLI in AML Relapse After Allo-HSCT | recruiting | N/A | 43 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT05862285 | A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study(UmbrellaMAX) | recruiting | Phase 3 | 100 | Hoffmann-La RocheINDUSTRY | 15 | Sep 2, 2026 | clinicaltrials |
| NCT05939180 | VA vs DA for Newly Diagnosed Hig-risk AML | recruiting | Phase 2 / Phase 3 | 116 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT06469944 | Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06) | recruiting | Phase 1 / Phase 2 | 160 | Merck Sharp & Dohme LLCINDUSTRY | 12 | Sep 2, 2026 | clinicaltrials |
| NCT06567015 | Study of FIH of STX-241 in Locally Advanced or Metastatic NSCLC Resistant to EGFR TKIs(STX-241 FIH) | recruiting | Phase 1 / Phase 2 | 171 | Pierre Fabre MedicamentINDUSTRY | 7 | Sep 2, 2026 | clinicaltrials |
| NCT06812065 | Randomized Controlled Clinical Trial of Hyperthermia and Hydrogen Peroxide 3% in the Treatment of Cutaneous Warts | recruiting | N/A | 300 | First Hospital of China Medical UniversityOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT06972771 | Trop2-targeting NIR-II Molecular Probe for Guided Identification of Non-Muscle-Invasive Bladder Cancer | recruiting | — | 40 | Yunnan Cancer HospitalOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT07003737 | Blinatumomab Intensification for MRD-Negative Acute B-Cell Lymphoblastic Leukemia Before Allogeneic Hematopoietic Stem Cell Transplantation | recruiting | N/A | 114 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT07076836 | Zusanli (ST36) Electroacupuncture Treatment for Neoadjuvant Immunotherapy in Non-Small Cell Lung Cancer | recruiting | N/A | 82 | West China HospitalOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT07083154 | Mazdutide in Type 2 Diabetes With Early-Stage Cognitive Impairment (LIGHT-COG Study) | recruiting | Phase 3 | 420 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT07138755 | The Efficacy and Safety of the Combination of PD-1 With Chemotherapy and Adaptive Radiotherapy Strategy in the Treatment of Stage III Non-small Cell Lung Cancer Patients | recruiting | Phase 2 | 35 | The Third Xiangya Hospital of Central South UniversityOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT07183878 | Venetoclax-Enhanced BUCY vs. Standard BUCY Conditioning in High-Risk AML and MDS Patients Undergoing Allo-HSCT (Ven-BUCY Study)(Ven-BUCY) | recruiting | N/A | 138 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT07192614 | A Study to Learn How Safe AZD6621 is, How Well it Works, and How it Moves Throughout the Body Over Time, in Adult Male Participants With Metastatic Prostate Cancer(ACTIVATED-4-PC) | recruiting | Phase 1 / Phase 2 | 52 | AstraZenecaINDUSTRY | 9 | Sep 2, 2026 | clinicaltrials |
| NCT07215650 | Clinical Study of Cizutamig in Generalized Myasthenia Gravis (gMG) | recruiting | Phase 1 | 44 | Candid TherapeuticsINDUSTRY | 1 | Sep 2, 2026 | clinicaltrials |
| NCT07252739 | KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J) | recruiting | Phase 2 | 140 | Merck Sharp & Dohme LLCINDUSTRY | 13 | Sep 2, 2026 | clinicaltrials |
| NCT07253194 | Electroacupuncture on Postoperative Urinary Retention After Radical Surgery for Cervical Cancer | recruiting | N/A | 208 | Lu ChaoOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT07350863 | U69-CART-Cells For R/R T-ALL | recruiting | Phase 1 | 12 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT07354074 | Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP | recruiting | Phase 2 | 50 | Novartis PharmaceuticalsINDUSTRY | 13 | Sep 2, 2026 | clinicaltrials |
| NCT07413757 | CHOICE:Decision Factor of EGFR-TKI in Chinese IV NSCLC(CHOICE) | recruiting | — | 590 | AstraZenecaINDUSTRY | 1 | Sep 2, 2026 | clinicaltrials |
| NCT07463248 | PULSAR Combined With Fecal Microbiota Transplantation for Advanced Hepatocellular Carcinoma Progressing After First-Line Targeted-Immunotherapy | recruiting | Phase 2 | 64 | Wang XinOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT07490938 | Electroacupuncture vs. Auricular Acupressure vs. Waitlist Control for Breast Cancer Endocrine Therapy-Related Joint Pain(EASE) | recruiting | N/A | 200 | First Teaching Hospital of Tianjin University of Traditional Chinese MedicineOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT07532538 | A Machine Learning-Based Risk Prediction Model for Head and Neck Cancerous Lesions(ML-HNC-Risk) | recruiting | — | 3,000 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT07562581 | A Phase 2 Study of Luvometinib Combined With Anlotinib in KRAS-mutated NSCLC | recruiting | Phase 2 | 48 | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.INDUSTRY | 1 | Sep 2, 2026 | clinicaltrials |
| NCT07622186 | A Study of SKB571 Combination Therapy in Participants With Non-Small Cell Lung Cancer (NSCLC) | recruiting | Phase 2 | 150 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 2, 2026 | clinicaltrials |
| NCT07625423 | Intratumoral Injection of Recombinant Human Endostatin Adenovirus (EDS01) for the Treatment of Recurrent or Metastatic Head and Neck Tumors(EDS01 HN) | recruiting | Phase 1 | 9 | West China HospitalOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT07719959 | A Randomized Controlled Trial of 3D Airway Reconstruction for Precise Double-Lumen Bronchial Intubation | recruiting | N/A | 174 | Peking Union Medical College HospitalOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT07766226 | Online Sharing for Head & Neck Cancer Support | recruiting | N/A | 120 | West China HospitalOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT07790809 | Safety and Short-term Outcomes of Modular Robotic System for Siewert II/III Gastroesophageal Junction Cancer(ROBOT-GEJ) | recruiting | N/A | 25 | The First Hospital of Jilin UniversityOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT07795437 | GPC3-Targeted PET Imaging of 18F-X12 in Hepatocellular Carcinoma | recruiting | N/A | 100 | Peking University First HospitalOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT07795528 | Postoperative Circulating Tumor DNA Monitoring in Stage I-III Driver-Mutant Colon Adenocarcinoma(ADX-DRIVER-CRC) | recruiting | — | 392 | Ruijin HospitalOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT07799922 | IRE After Targeted Immunotherapy in HCC With Portal Vein Tumor Thrombus | recruiting | N/A | 60 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT07799935 | IRE After Chemotherapy for Locally Advanced Pancreatic Cancer | recruiting | N/A | 60 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT05727176 | Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement(FOENIX-CCA4) | recruiting | Phase 2 | 120 | Taiho Oncology, Inc.INDUSTRY | 13 | Sep 1, 2026 | clinicaltrials |
| NCT06414460 | Study of ISM3412 in Participants With Locally Advanced/Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 146 | InSilico Medicine Hong Kong LimitedINDUSTRY | 2 | Sep 1, 2026 | clinicaltrials |
| NCT06712355 | Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer | recruiting | Phase 3 | 621 | BioNTech SEINDUSTRY | 14 | Sep 1, 2026 | clinicaltrials |
| NCT06787456 | "Xijiang Project" Screening Cohort for NPC | recruiting | — | 1,000,000 | Ming-Yuan ChenOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT07179744 | Regional Radiotherapy Omission in Low-Risk Node Positive Breast Cancer | recruiting | — | 635 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT07294664 | PDL1/TGFβ In Combination With SHR2554 or Apatinib And Chemotherapy For First - Line Treatment Of Gastric Cancer | recruiting | Phase 2 | 78 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT07371234 | Low-Dose Radiotherapy and Anti-PD-1 Immunotherapy as Neoadjuvant Treatment for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma | recruiting | Phase 2 | 22 | Rui YouOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT07381660 | SBRT Versus Surgical Resection for Small HCC | recruiting | Phase 3 | 390 | Sun Yat-sen UniversityOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT07432022 | A Phase I/II Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of the EMB-07 Combination Therapy in Patients With Aggressive B-Cell Non-Hodgkin Lymphoma | recruiting | Phase 1 / Phase 2 | 115 | Shanghai EpimAb Biotherapeutics Co., Ltd.INDUSTRY | 1 | Sep 1, 2026 | clinicaltrials |
Data updated 24 days agoSource updated unknownsource: clinicaltrials